> Detailanzeige

Verheyen, Nicolas; Schmid, Johannes; Kolesnik, Ewald; Schwegel, Nora; Späth, Johannes; Kattnig, Lydia; Riepl, Hermann; Zach, David; Santner, Viktoria; Höller, Viktoria; Pilz, Stefan; Tomaschitz, Andreas; Fuchsjäger, Michael; Fahrleitner‐Pammer, Astrid; Dimai, Hans Peter; Obermayer‐Pietsch, Barbara; Fruhwald, Friedrich; Scherr, Daniel; Zirlik, Andreas; von Lewinski, Dirk; Ablasser, Klemens

Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction
  • Beteiligte: Verheyen, Nicolas; Schmid, Johannes; Kolesnik, Ewald; Schwegel, Nora; Späth, Johannes; Kattnig, Lydia; Riepl, Hermann; Zach, David; Santner, Viktoria; Höller, Viktoria; Pilz, Stefan; Tomaschitz, Andreas; Fuchsjäger, Michael; Fahrleitner‐Pammer, Astrid; Dimai, Hans Peter; Obermayer‐Pietsch, Barbara; Fruhwald, Friedrich; Scherr, Daniel; Zirlik, Andreas; von Lewinski, Dirk; Ablasser, Klemens
  • Erschienen: Wiley, 2024
  • Erschienen in: ESC Heart Failure, 11 (2024) 3, Seite 1730-1738
  • Sprache: Englisch
  • DOI: 10.1002/ehf2.14741
  • ISSN: 2055-5822
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractAimsChronic heart failure is associated with a bone‐catabolic state and increases the risk of osteoporosis and fractures. Prospective studies investigating the clinical relevance of bone disease in heart failure are lacking. We aimed to assess the prevalence and prognostic impact of osteoporosis and vertebral fractures (VFs) in chronic heart failure with reduced ejection fraction (HFrEF).Methods and resultsSymptomatic outpatients with chronic heart failure and a previous diagnosis of overtly reduced left ventricular ejection fraction < 40% on stable, optimal HFrEF therapy and left ventricular ejection fraction < 50% at enrolment were included into a prospective single‐centre study. Osteoporosis was determined with dual‐energy X‐ray absorptiometry and defined as a T‐score ≤ 2.5 at any site. VFs were assessed using X‐ray of both thoracic and lumbar spine applying the semiquantitative Genant score. We enrolled 205 patients (22% women), with a median age of 66 (IQR 58–74) years. Median left ventricular ejection fraction was 37 (IQR 30–43) % and median N‐terminal pro B‐type natriuretic peptide was 964 (IQR 363–2173) pg/mL. Osteoporosis, as defined by bone mineral density, and at least one VF were prevalent in 31 (15%) and 29 patients (14%). Osteoporosis or VF were present in 55 patients (27%) and 5 patients (2%) had both osteoporosis and a VF. During a median follow‐up of 4.7 (IQR 4.0–5.3) years, 18 patients (9%) died due to cardiovascular (CV) cause, and 46 patients (22%) had a worsening heart failure (WHF) hospitalization. In multivariate Cox regression analyses, presence of VF independently predicted CV death (HR 2.82, 95% CI 1.04–7.65, P = 0.042), WHF hospitalizations (HR 2.39, 95% CI 1.18–4.82, P = 0.015), and a composite endpoint of CV death and WHF hospitalizations (HR 2.44, 95% CI 1.23–4.82, P = 0.011). Osteoporosis was not significantly associated with CV events.ConclusionsIn a prospective study, bone disease affected every fourth patient with HFrEF, and patients with VF at baseline had a two‐fold risk of subsequent CV death or WHF hospitalization. Prevalent bone disease, particularly VF, should be considered as a clinically relevant comorbidity in HFrEF.
  • Zugangsstatus: Freier Zugang